长期口服核苷（t）类似物治疗期间乙型肝炎病毒相关肝硬化

StephenW

World J Gastroenterol. 2017 Jan 14;23(2):297-305. doi: 10.3748/wjg.v23.i2.297.
3-Dimensional liver volume assessment in patients with hepatitis B virus-related liver cirrhosis during long-term oral nucleos(t)ide analogues therapy.Lee CH1, Kim IH1, Moon JC1, Seo SY1, Kim SH1, Kim SW1, Lee SO1, Lee ST1, Kim DG1, Yang JD1, Yu HC1.
Author information

• 1Chang Hun Lee, In Hee Kim, Jin Chang Moon, Seung Young Seo, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, Dae Ghon Kim, Division of Gastroenterology, Department of Internal Medicine, Chonbuk National University Medical School and Hospital, Jeonju 561-180, South Korea.
  

AbstractAIM: To assess the effect of long-term oral nucleos(t)ide analogues (NUCs) therapy on liver volume change in patients with suppress hepatitis B virus (HBV)-related liver cirrhosis.
METHODS: We reviewed the data of naïve patients with HBV-related liver cirrhosis, who had taken oral NUCs therapy, between 2003 and 2007 at Chonbuk University Hospital. We analyzed two consecutive sets of abdominal computerized tomography scans-one at the time of treatment initiation and another at the second-year follow-up. Liver volume was calculated by 3-dimensional liver extraction volumetry program.
RESULTS: A total of 55 patients (34 males) were included. There was 114.3 mL ± 167.8 mL (12.9% ± 17.9%) of increase in liver volume during the two years of NUCs therapy (993.8 mL ± 242.8 mL at baseline vs 1108.1 mL ± 263.3 mL at two-year follow-up, P < 0.001). The ratio of the measured baseline liver volume to the estimated standard liver volume was improved from 70.8% to 78.0%. An increase in liver volume was shown not only in patients with compensated cirrhosis (P = 0.046) but also in those with decompensated cirrhosis (P < 0.001). Significant factors for volume increases were Child-Turcotte-Pugh grade and model for end-stage liver disease score improvement without virological breakthrough. In multiple linear regression analysis, delta albumin and delta alanine aminotransferase levels showed a significant association with the increase in liver volume (P = 0.002 and 0.005, respectively).
CONCLUSION: Long-term oral NUCs therapy in patients with HBV-related liver cirrhosis lead to significant increase in liver volume assessed with 3-dimensional liver extraction volumetry program.


KEYWORDS: Antiviral agents; Computer-assisted; Image processing; Liver cirrhosis; Liver regeneration

PMID:28127203DOI:10.3748/wjg.v23.i2.297

StephenW

世界胃肠病学杂志。 2017 Jan 14; 23（2）：297-305。 Doi：10.3748 / wjg.v23.i2.297。
长期口服核苷（t）类似物治疗期间乙型肝炎病毒相关肝硬化患者的3维肝体积评估。
Lee CH1，Kim IH1，Moon JC1，Seo SY1，Kim SH1，Kim SW1，Lee SO1，Lee ST1，Kim DG1，Yang JD1，Yu HC1。
作者信息

Sang Wook Kim，Seung Ok Lee，Soo Teik Lee，Dae Ghon Kim，Department of Gastroenterology，Department of Internal Medicine，Chonbuk National University Medical School。 1Chang Hun Lee，In Hee Kim，Jin Chang Moon，Seung Young Seo，Seong Hun Kim，And Hospital，Jeonju 561-180，South Korea。

抽象
目标：

评估长期口服核苷（类似物）（NUC）治疗对抑制性乙型肝炎病毒（HBV）相关肝硬化患者的肝脏体积变化的影响。
方法：

我们分析了两组连续的腹部计算机断层扫描 - 一个在治疗开始时，另一个在2003年至2007年在Chonbuk大学医院接受口服NUC治疗的HBV相关性肝硬化患者的数据的研究。第二年随访。通过三维肝脏提取容积法计算肝脏体积。
结果：

共包括55名患者（34名男性）。在两年的NUC治疗期间，肝脏体积增加114.3 mL±167.8 mL（12.9％±17.9％）（基线时为993.8 mL±242.8 mL，两年随访时为1108.1 mL±263.3 mL，P < 0.001）。测量的基线肝脏体积与估计的标准肝脏体积的比率从70.8％提高到78.0％。肝脏体积的增加不仅显示在具有显着的体积增加因子的患者中，Child-Turcotte-Pugh分级和用于终末期肝脏疾病得分改善而无病毒学突破的模型。在多元回归分析中（P = 0.046），在失代偿性肝硬化分析中，δ白蛋白和δ丙氨酸氨基转移酶水平与肝脏体积的增加呈显着相关（分别为P = 0.002和0.005）。
结论：

长期口服NUCs治疗HBV相关肝硬化患者导致肝体积评估的显着增加与3维肝提取容量计划。
关键词：

订购本论文肝胆硬化的副本

PMID：
28127203
DOI：
10.3748 / wjg.v23.i2.297